

---

## Active Biotech Q2 2024 - Both Myelofibrosis Studies Soon Recruiting

Redeye comments on Active Biotech's Q2 report. New results with naptumomab + docetaxel were presented by NeoTX in the quarter, with inconclusive results. The US study in myelofibrosis is ready to recruit the first patient, while the European study is estimated to be ready to begin recruitment in Q3.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Active Biotech Q2 2024 - Both Myelofibrosis Studies Soon Recruiting](#)